By: Michelle Diament
The Food and Drug Administration is ending its approval of Wellcovorin, the branded version of leucovorin. (FDA/Flickr)
Michelle Diament is a Co-Founder at NewsBreak. She covers a range of topics including law and legal affairs, legislation, health and wellness, government and politics, and special education, with a particular focus on elections, public policy, and special needs advocacy. Michelle's work has been featured in Disability Scoop.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)


Not enough data
Michelle Diament's coverage primarily focuses on national U.S. government announcements, legal policy regulation, and data citations related to disability services, Medicaid, ADA, SSI, education department issues and employment topics. She often covers stories related to the impact of regulations on disability service providers and individuals with disabilities.
When reaching out to Michelle with pitches or expert commentary ideas, consider offering insights into government policies affecting disability services and advocacy efforts for people with disabilities in the United States. Additionally, providing analysis of relevant data or citing recent research findings would likely be well-received by her based on her previous articles.
Given Michelle's focus on national news relating to these specific areas within the U.S., it may be beneficial to tailor pitches around developments that directly impact federal policies or have implications at a broader level within the country.
This information evolves through artificial intelligence and human feedback. Improve this profile .